TREM1 and glioblastoma: To determine whether the suppression of the TREM1+-glioblastoma microenvironment leads to a reduction in cell fusion events, we analyzed cell fusion events between tumor and myeloid-derived cells in the fluorescently defined GL261 glioblastoma model following mice treatment with SRI42127 (15 mg/kg, twice per day for 18 days) versus control treatment.